8-KLeadership ChangesExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Executive Changes (Aug 4, 2026)

Filed August 4, 2026For Securities:JNJ

Summary

Johnson & Johnson (JNJ) has filed an 8-K reporting a significant leadership transition. Effective September 1, 2026, Jennifer Taubert will retire from her role as Executive Vice President, Worldwide Chairman of Innovative Medicine and as a member of the Executive Committee. This departure marks the end of Ms. Taubert's tenure in a crucial leadership position overseeing the company's pharmaceutical segment. While the filing itself is brief and primarily announces the retirement, investors should note that the company has attached a press release (Exhibit 99.1) providing further details. The announcement signals a change at the highest levels of the Innovative Medicine business, and the market will likely look to future communications from Johnson & Johnson for information regarding succession plans and the strategic direction of this key segment under new leadership. Investors are advised to review the accompanying press release for a more comprehensive understanding of the transition and its potential implications.

Key Highlights

  • 1Jennifer Taubert, EVP, Worldwide Chairman of Innovative Medicine, to retire effective September 1, 2026.
  • 2Ms. Taubert also a member of Johnson & Johnson's Executive Committee.
  • 3The filing is an 8-K, indicating a material event for the company.
  • 4A press release (Exhibit 99.1) is attached to this filing for additional details.
  • 5This leadership change pertains to the critical Innovative Medicine segment.

Frequently Asked Questions

Jennifer Taubert, Executive Vice President, Worldwide Chairman of Innovative Medicine, will retire effective September 1, 2026.

Ms. Taubert held a key leadership position as the head of the Innovative Medicine segment and was also a member of the company's Executive Committee, indicating significant influence over the pharmaceutical business.

The company has attached a press release, Exhibit 99.1, to this Form 8-K filing, which is expected to contain further details regarding Ms. Taubert's retirement and potentially succession plans.

This filing specifically announces a leadership change and does not include financial statements or performance data. However, significant leadership transitions, especially in a key segment like Innovative Medicine, can have indirect impacts on investor confidence and future strategic direction, which may influence financial performance over time.